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Drugs acting at dopamine D2 receptors (D2R) are
commonly used to alleviate symptoms produced by
diseases such as Parkinson’s disease, schizophre-
nia, and depression. A limitation to the use of these
drugs is that they sometimes afflict patients with se-
vere side effects. This review discusses recent evi-
dence for several proteins that represent novel medi-
ators of the downstream consequences of D2R
activation, since selective targeting of particular D2R-
mediated signaling pathways could lead to the devel-
opment of improved treatments for these devastat-
ing diseases.
The goal of this review is to briefly summarize our cur-
rent knowledge about dopamine D2 receptors (D2Rs),
in light of two recent papers that have advanced our
understanding of the complexity of the intracellular
physiology that is coordinated by this receptor. Dopa-
mine receptors are G protein-coupled receptors and
belong to two main families (reviewed in Missale et al.,
1998; Neve et al., 2004): the D1-like receptor subfamily
(D1R), including the D1 and D5 receptors; and the D2-
like subfamily, including the D2, D3, and D4 receptors.
D1Rs activate adenylyl cyclase (AC) via their coupling
to Gs/Golf, while D2Rs are Gi/o linked and release Gαi/o
and Gβγ subunits. Classically, D2R function has been
thought of in terms of antagonism of cAMP-dependent
signaling, where Gαi subunits bind to and inhibit ade-
nylyl cyclases, preventing production of cAMP and ac-
tivation of protein kinase A (PKA) (Figure 1A). In this
view, the primary action of dopamine is to activate neu-
rons through the D1 receptor, and this activation is
reduced by concurrent activation of the D2 receptor.
Although some neurons have only D2 or only D1 recep-
tors, D2/D1 antagonism is widely observed. In striatal
neurons, DARPP-32 is a primary target of PKA, and
DARPP-32 is involved in many dopaminergic actions,
including D2R inhibition of the cAMP-dependent
system.
D2 receptors also alter intracellular signaling through
Gβγ subunits, which can act at a number of intracellular
targets (Figure 1B) (reviewed in Neve et al., 2004). In
addition to direct interaction of Gβγ with several types
of ion channels, Gβγ subunits facilitate calcium release
from intracellular calcium stores. To further illustrate the
complexity of the downstream effectors activated by
D2R, G subunits can activate the MAP kinase systemβγ*Correspondence: bonci@itsa.ucsf.eduthrough several different pathways, which can involve
the phosphinositide 3-kinase, Ras, and transactivation
of a growth factor receptor.
The activity of the D2R itself is regulated by desensi-
tization, where continuous agonist application results
in phosphorylation of the D2R (e.g., by the G protein
receptor kinase GRK2), leading to uncoupling of recep-
tors from G protein activation and promotion of binding
of arrestin and receptor internalization (Gainetdinov et
al., 2004) (Figure 1B). Also, as described below, Beau-
lieu et al. (2005) provide novel evidence that β-arrestin
2 can also facilitate some aspects of D2R signaling.
From an anatomical standpoint, the D2R is present
in many areas of the central nervous system, but it is
preferentially located in the substantia nigra pars com-
pacta, the ventral tegmental area, the striatum (which
includes the nucleus accumbens shell and core and the
dorsal striatum), olfactory tubercule, and the pituitary
gland (reviewed in Missale et al., 1998). Functionally,
like many G protein-coupled receptors, D2R can be lo-
cated both presynaptically, regulating release of dopa-
mine and other neurotransmitters, and postsynapti-
cally, where it can exert a variety of functions, ranging
from inhibition of long-term depression at midbrain ex-
citatory synapses, to inhibition of calcium channels, to
control of pacemaker activity and resting potential
through activation of GIRK channels (Hopf et al., 2003;
Jones and Bonci, 2005; and references therein).
Role of Dopamine D2 Receptors in Neurological
and Psychiatric Diseases
D2R regulatory molecules are also interesting as poten-
tial therapeutic targets because dopaminergic dysregu-
lation is implicated in a number of neurological and
psychiatric conditions, but no change in dopamine re-
ceptor abundance has been observed. Dysregulation of
dopamine signaling could also be due to alterations of
the D2R itself: while a missense mutation in the DRD2
gene causes myoclonus dystonia, other mutations at
D2Rs have been associated with a variety of neurologi-
cal and psychiatric diseases ranging from Parkinson’s
disease to substance abuse, schizophrenia, and bipo-
lar disorders (for a complete list of studies, please go
to http://geneticassociationdb.nih.gov).
Of particular relevance to this brief review is the po-
tential role of abnormal D2R activity in mediating symp-
toms associated with schizophrenia and depression.
D2R antagonists have been pursued for a long time as
antipsychotic agents. Although there is general con-
sensus that every antipsychotic drug must inhibit D2Rs
to be clinically effective for schizophrenia, there is a
clear dissociation between the relatively low therapeu-
tic benefit and their high pharmacological selectivity as
D2R antagonists (reviewed in Miyamoto et al., 2005).
Thus, while extensive research on therapeutic agents
acting at D2Rs has been performed, the mechanism
underlying the therapeutic properties of these drugs re-
mains to be defined. However, animal studies support
a role for the D2R in schizophrenia. Schizophrenia is
associated with supersensitivity to dopamine, and a
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Figure 1. Evolution of the Dopamine D2R-Dependent Intracellular r
Pathways
s
Panels (A) and (B) summarize how our knowledge of the dopamine
sD2R-dependent intracellular pathways has evolved over time, from
minhibition of cAMP signaling (A), to signaling through Gαi and multi-
iple Gβγ-dependent pathways and regulation both by internalization
and by molecules such as RGSs (B). Panel (C) refers to the finding p
from the two papers by Beaulieu et al. (2005) and Park et al. (2005). p
t
1
number of treatments that enhance dopamine sensitiv- 2
ity in rodents enhance the number of D2Rs in the high- p
affinity state (Seeman et al., 2005). Further, sensori- i
motor gating, which is impaired in schizophrenics and t
disrupted by dopamine in rodents, requires the D2R but e
not D3R or D4R (Ralph et al., 1999). Thus, a deeper o
understanding of the complex D2R-dependent intracel- w
lular pathways is likely to represent a key step to aid i
scientists in designing more effective antipsychotics. B
A key role for dopamine in some of the symptoms β
commonly observed in depressed patients, such as an- u
hedonia or decreased motivation, has also been sug- i
gested for years (reviewed in Dailly et al., 2004). In ani-
mal models of depression, like the forced swim test, t
the efficacy of the selective dopamine reuptake inhibi- p
tor GBR 12909 as an antidepressant has been shown. p
There is also evidence for a synergistic/cooperative ef- s
fect of D2R agonists (but also D1R or D3R agonists) o
with traditional antidepressants that belong to the se- b
lective serotonin reuptake inhibitor (SSRI) family, since (
pthese SSRIs coadministered with a dopamine agonistignificantly improve the rodent’s performance on the
orced swim test. Human studies provide further sup-
ort for a role of D2R in depression because some anti-
epressants act in part by blocking dopamine reuptake
nd by activating dopamine receptors. In addition, a
ompensatory upregulation of D2Rs has been observed
n the striatum of patients suffering from depression.
aken together, these studies suggest that enhancing
opamine signaling might represent a promising comple-
entary target to traditional antidepressants, especially
hen anhedonia and apathy are primary symptoms.
egulation of D2Rs by Intracellular
inding Partners
t has become clear in recent years that few receptors
ct in isolation, but instead exist in a complex with reg-
latory and scaffolding molecules. New promising in-
ights come from two recent studies by Beaulieu et al.
2005) and Park et al. (2005), both of which have iden-
ified new intracellular proteins and pathways that are
odulated by D2R activity.
The study by Beaulieu and colleagues provides evi-
ence that a member of the D2R receptor subfamily
nhibits the activity of the serine threonine kinase Akt
hrough a β-arrestin 2-dependent mechanism and that
his effect occurs through a newly discovered β-arres-
in/kinase/phosphatase signaling complex (Figure 1C)
hat is independent from the traditional cAMP-depen-
ent pathway. This suggests that β-arrestin plays a role
n signal transduction, in addition to its canonical role
n receptor internalization, through a complex com-
osed of the intracellular proteins Akt, β-arrestin 2, and
hosphatase PP2A. Combined with results from a pre-
ious study by the same group (Beaulieu et al., 2004),
hese results demonstrate that β-arrestin 2 is critical in
egulation of Akt and its downstream target glycogen
ynthase kinase (GSK) (Figure 1C). The authors also
how that activation of D2-like receptors is unable to
odulate the activity of the protein Akt in the striatum
n these mutant mice, suggesting that β-arrestin 2 ap-
ears to be critical for the dopamine-dependent de-
hosphorylation of Akt by allowing a specific associa-
ion between Akt and the phosphatase PP2A (Figure
C). Behaviorally, genetic knockout of either β-arrestin
or GSK reduces the acute locomotor response to
sychostimulants, and β-arrestin 2 knockouts lack the
ncreased exploratory activity in novel environments
hat is present in normal mice. This study is particularly
xciting in that it opens new avenues for investigation
f D2R-mediated, cAMP-independent intracellular path-
ays. In addition, alterations in Akt and GSK may be
mplicated in schizophrenia (Emamian et al., 2004), and
eaulieu and colleagues suggest that the D2R/Akt/
-arrestin pathway they have identified might contrib-
te to the dopaminergic dysregulation thought to occur
n schizophrenic patients.
The study by Park and colleagues shows that pros-
ate apoptosis response 4 (Par-4) is a novel binding
artner of the D2R. Par-4 has been implicated in apo-
tosis and neuronal death, but its presence in synapses
uggests other unidentified roles in neuronal physiol-
gy. Par-4 interacts with the D2R at the calmodulin
inding motif in the third cytoplasmic loop of the D2R
Figure 1C). Calmodulin (CM) binding to the D2R dis-
laces Par-4 and inhibits D2R activation of G proteins.
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cium/CM-mediated inhibition of D2R function. Loss of
Par-4, either through RNAi in culture or in a mutant
mouse with a deletion in the leucine zipper domain that
binds the D2R (Par-4LZ), blocks D2R action and
thereby facilitates D1R-mediated activation of adenylyl
cyclase and CREB phosphorylation. Most interesting is
the observation that Par-4LZ mice exhibit a depres-
sion-like syndrome. For example, in the forced swim
test, rodents swim around for a while, but eventually
give up and become immobile. A shorter latency to im-
mobility (“giving up sooner”) is considered consistent
with a depression-like syndrome, as it is reversed by
most antidepressants. Par-4LZ mice exhibit signifi-
cantly shorter latencies to immobility relative to wild-
type mice. Importantly, Par-4LZ mice do not exhibit
differences in tests of anxiety, suggesting that earlier
immobility is not secondary to responsiveness to anxi-
ety and stress.
To understand the present results in the context of
depression, it is critical to understand the altered cellu-
lar mechanism within neurons that mediates depres-
sion-like behaviors. It is clear that a number of neuro-
chemical systems can be altered during depression
and might contribute to the clinical syndromes ob-
served in humans (Manji et al., 2001; Nestler et al.,
2002). As mentioned above, links between dopamine
signaling and depression are tantalizing but still some-
what tenuous. Certainly dopamine is important for mo-
tivation and responsiveness to salient stimuli, and de-
creased motivation and loss of responsiveness can be
observed in depressed humans. Depression in Parkin-
son’s patients also supports the idea that reduced
dopamine function is causally implicated in the mani-
festation of depression. Thus, impaired D2R function
secondary to loss of Par-4 represents an attractive hy-
pothesis for the presence of a depression-like syn-
drome in Par-4LZ mice. However, in striatal neurons,
loss of Par-4 is associated with decreased D2R func-
tion, but also with facilitation of D1 receptor activation
of the PKA system and enhanced CREB phosphoryla-
tion relative to wild-type neurons. Thus, depression-like
symptoms in Par-4LZ mice might reflect an altered
balance between D1R and D2R signaling rather than
simply decreased dopaminergic activation.
Relating D2 or D1 receptor function to depression is
complicated by the fact that the exact role of D2 and
D1 in reward and motivation is still a matter of debate,
since activation of these receptors produces a wide
range of functional responses that are dependent upon
the activity state of the neurons. For example, a number
of studies have found a role for both D2 and D1 in the
nucleus accumbens in motivation and goal-directed
behaviors (Yun et al., 2004; and see references in Hopf
et al., 2003). Brain slice electrophysiology experiments
have found D1/D2 synergy in several brain regions, in-
cluding the nucleus accumbens (Hopf et al., 2003). In-
terestingly, Par-4 binds an atypical isoform of PKC
(aPKC) in addition to the D2R, and aPKCs are neces-
sary for the D2 (and D1) receptor-dependent excitation
of nucleus accumbens shell neurons (Hopf et al., 2005).
Dopamine receptor activity in regions other than the
nucleus accumbens can also contribute to motivated
behaviors, but we would like to emphasize here thatthere are still significant gaps in our understanding of
the relationship between D2 and D1 receptors and ba-
sic motivational drives, let alone depression.
The results from these papers are particularly inter-
esting because it is possible that selective restoration
of β-arrestin 2 or Par-4 function within particular brain
regions of β-arrestin 2 or Par-4 mutant mice, perhaps
using a viral approach, would help in identification of
the brain regions responsible for schizophrenia-like or
depression-like symptoms. The ability to pinpoint the
brain region(s) responsible for these behavioral abnor-
malities would significantly advance our understanding
of the critical neuronal pathways involved and perhaps
suggest these new pathways as novel therapeutic in-
terventions. Along this line, the observation that Par-4
did not bind to other serotoninergic and adrenergic Gi-
linked receptors and that cAMP accumulation in re-
sponse to these neuromodulators was not altered in
Par-4LZ mice is encouraging and strengthens the
possible specificity of the interaction of Par-4 and the
D2R and the relationship between the D2R and de-
pression.
Interesting questions remain about the exact molecu-
lar mechanism through which Par-4 regulates D2R func-
tion. For example, Kabbani et al. (2002) demonstrated
that the protein neuronal calcium sensor 1 (NCS-1), which
had been previously shown to regulate several aspects
of neurotransmission, can be coimmunoprecipitated
from striatal membranes with the D2R and with GRK2.
Further, Kabbani et al. provided evidence that NCS-1
can reduce D2R phosphorylation and internalization
and can facilitate D2R-mediated inhibition of adenylyl
cyclase activation. NCS-1 regulation of D2R is likely
due to a calcium-dependent association of NCS-1 with
GRK2, suggesting that NCS-1 regulates D2R function
through inhibition of GRK2, analogous to NCS-1 regula-
tion of rhodopsin by inhibition of GRK1.
It will be interesting to determine whether Par-4 might
regulate D2R through altered phosphorylation or inter-
nalization through interaction with NCS-1, GRK, or by
some other mechanism. For example, Par-4 could regu-
late D2Rs through RGS proteins, several of which have
been shown to attenuate D2R function (Rahman et al.,
2003; Jeanneteau et al., 2004). In addition, Par-4 facili-
tates actin bundling and might perform a scaffolding
function, perhaps similar to the requirement for the ac-
tin binding protein filamin for plasma membrane local-
ization of D2R (Lin et al., 2001). The GSK/Akt pathway
can also regulate the actin cytoskeleton by enhancing
actin filament stability (Owen and Gordon-Weeks,
2003), suggesting that Par-4 may regulate D2R function
through modulation of the β-arrestin 2/Akt/PP2A path-
way described by Beaulieu et al. (2005). This would be
particularly interesting because the D2R-mediated ef-
fects in Beaulieu’s study are not apparent until after 30
or more minutes, while Par-4 regulation of D2R function
is apparent earlier, suggesting that D2R activation of
GSK might be regulated on different time scales by dif-
ferent intracellular signaling mechanisms.
Park et al. also suggest, based on the observation
that motor coordination is not disrupted in the Par-
4LZ mice but is disrupted in the D2 knockout or after
OHDA lesions, that Par-4 may mediate only some of the
functions of the D2R. This raises the interesting ques-
Neuron
338tion of whether there are different populations of D2Rs, l
linked to different effectors via selective scaffolding/ i
regulatory proteins. These different populations might m
represent variation in isoforms, affinity states, multimer- o
ization, or glycosylation-state (see Lee et al., 2003; t
Neve et al., 2004; Seeman et al., 2005; references in i
Park et al., 2005) or might involve the same D2R vari-
ants, which are segregated functionally into different in-
Stracellular microdomains. However, according to Beau-
lieu et al., removal of β-arrestin 2 alters regulation of
Bboth cAMP-independent and cAMP-dependent signal-
Jing. Thus, different molecules might contribute to one S
or multiple effector pathways of the D2R.
B
It is also important to note that the majority of studies z
directly examining intramolecular interactions have W
been performed in immortalized cells or neuronal cul- B
tures and often involve overexpression of the mole- G
cules of interest. The more difficult studies showing D
similar interactions in intact neurons would strengthen C
the in vivo relevance of such observations. Behavioral E
Gexperiments involving knockout mice or viral-mediated
genetic manipulation are very helpful in this regard, al- G
Cthough it is more difficult in the intact brain to be certain
Hthat removal of a particular molecule (e.g., Par-4) is hav-
(ing its behavioral effect through a particular target (e.g.,
Hthe D2R). In many cases, brain slice experiments could
Aalso be very useful in discerning the details of molecu-
Jlar interactions. For example, Bartlett et al. (2005) re-
(cently showed that the protein GASP plays a critical
Jrole in activation-dependent reduction in D2R function
Kby targeting internalized D2R to the degradative path-
sway. Further, patch clamp electrophysiology was used
Kto demonstrate that prolonged D2R activation led to
6persistent loss of D2R function in VTA DA neurons, but
Lthat intracellular perfusion with an antibody that blocks
Lthe function of GASP allowed recovery of D2R function.
RBecause patch clamp allows more precise control of
Mthe intracellular milieu (and, for example, the level of
5
free calcium) as well as perfusion of peptides and other
Mproteins, this technique cannot only verify the impor-
(
tance of proposed signaling interactions under physio-
M
logically relevant conditions, but also can directly assay M
the physiological consequences of such signaling in in-
N
tact neurons. M
Conclusions N
These studies represent exciting additions to the infor- R
mation relating the function of particular molecules with O
behavior. In particular, because of the strong link be- 6
tween dopamine dysregulation and several psychiatric P
disorders, identification of novel pathways for regula- f
2tion of dopamine receptor function may open intriguing
new avenues for understanding the etiology of such R
Cdisorders and perhaps for the development of novel
atherapeutic interventions. However, we must temper
Rour enthusiasm in relation to the role of a specific mole-
bcule with the knowledge that neuronal signaling in vivo
Nis complex, with many neurochemicals and proteins in
Smultiple brain regions contributing to even the simplest
wof behaviors. For example, Peter Kalivas et al. (2005)
E
have shown that chronic cocaine self-administration al-
Y
ters the function of several different molecules and that J
normalization of the function of any one of these mole-
cules is sufficient to reduce reinstatement of cocaine
seeking. The lesson here is that multiple moleculesikely contribute to both normal and abnormal behav-
oral states. Thus, it is very exciting when a particular
olecule can be so elegantly linked to the expression
f interesting behaviors, but it is essential to remember
hat no molecule can get by without a little help from
ts friends.
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